Medical Educational Resource
The CIFFREO Study
This Industry Update Webinar is sponsored by Pfizer. This program is not sponsored, endorsed, or accredited by MDA.
This Industry Update Webinar for clinicians is presented by Pfizer and features information on the CIFFREO study. On June 15, 2022 at 12:00PM EST in a 30-minutes webinar, Dr. Kasia Labello, Global Clinical Lead for the Duchenne Muscular Dystrophy Gene Therapy Program at Pfizer, provided an overview of the CIFFREO study. The CIFFREO Study is a Phase 3, Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of mini-dystrophin Gene Therapy (fordadistrogene movaparvovec) in Ambulatory Boys with DMD.